Sapna Tandon, MD

A new #CRISPR-based clinical trial for #SickleCell disease is enrolling at UCSF. This is the first therapy in the U.S. to apply non-viral CRISPR gene editing to directly correct the genetic mutation that causes the disease. Read more: https://ow.ly/Smry50UfZi1

32

📺 Catch our conversation with Roger Li, MD, of Moffitt Cancer Center, on the final results of #CORE001, which investigated #cretostimogene plus #pembrolizumab for #BCG-unresponsive #NMIBC with #CIS. 👉 Find the Full Video Here:

17

🌟 Best of #ASMS2024 🌟 Fintiede Solutions is thrilled to share the groundbreaking advancements unveiled by Evosep at the #ASMS2024 conference in Anaheim! Evosep continues to push the boundaries in the field of proteomics, introducing innovations that are set to transform research and clinical diagnostics. 🔬 Key Innovations Announced: Fully Automated Workflows: - Capable of processing over 500 plasma samples per day. - Maximizes efficiency and minimizes manual intervention. - Ideal for accelerating drug discovery and supporting large-scale translational research. - Reduces cost per sample and environmental impact. Whisper™ Zoom Methods: - Enhances scalability and sensitivity for detailed and accurate proteomic analyses. - Unlocks the ability to detect low-abundant proteins and identify novel biomarkers. - Facilitates deeper biological insights into disease pathways. Evosep Biolabs: Center of Excellence for High Throughput Proteomics: - Specializes in high-throughput proteomics with automated sample preparation. - Offers access to state-of-the-art LC-MS/MS workflows and expert assay development. - Provides scalable capacity for outsourcing proteomics research projects. 🏆 Impact and Vision: Evosep's innovations are designed to make clinical proteomics 100x more robust and 10x faster, revolutionizing the landscape of proteomics research. These advancements are particularly aimed at accelerating drug discovery and enhancing proteomics-based diagnostics, ultimately improving patient care. We are proud to be part of this journey and look forward to the incredible breakthroughs these technologies will enable in the near future. #Evosep #Proteomics #ASMS2024 #ScientificInnovation #DrugDiscovery #TranslationalResearch #Biomarkers #ClinicalDiagnostics #automation #whisper

2

<!-- Content start --> South San Francisco, CA — July 3, 2024 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial (first-line) treatment for people with previously untreated, locally advanced unresectable or metastatic non-squamous non-small cell lung cancer (nSq NSCLC), did not meet its primary endpoints of progression-free survival (PFS) at its primary analysis with a hazard ratio (HR) of 1.27 [95% CI: 1.02,1.57] and overall survival (OS) at its first interim analysis with a HR of 1.33 [95% CI: 1.02, 1.73], which was immature. The combination of tiragolumab plus Tecentriq and chemotherapy showed reduced efficacy in both PFS and OS compared to the comparator arm in the intent-to-treat population, which includes Phase II and Phase III cohorts. The overall safety profile remains consistent with the safety profile previously observed for the combination of tiragolumab plus Tecentriq and chemotherapy, and no new or unexpected findings were identified. Based on these results, patients and investigators will be unblinded and we intend to halt the study. A communication will be sent to the investigators and results will be shared with health authorities and subsequently presented at an upcoming medical meeting. “These results are disappointing as it was our hope that this combination might yield improved outcomes for people living with metastatic non-squamous lung cancer,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. “We are thankful to all of the patients and healthcare professionals involved in the study, and we will leverage the learnings to inform our scientific understanding of the anti-TIGIT pathway and new avenues in cancer research.” Ongoing Phase III studies are investigating treatment settings and indications distinct from SKYSCRAPER-06. Based on today’s results, we will evaluate any relevant changes needed to the ongoing tiragolumab program. About SKYSCRAPER-06 study SKYSCRAPER-06 is a global Phase II/III, randomized, placebo-controlled and double-blinded study evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy as an initial (first-line) treatment versus pembrolizumab and chemotherapy in 542 people with non-squamous non-small cell lung cancer. Primary endpoints are overall survival (OS) and progression-free survival (PFS). About tiragolumab Tiragolumab is an investigational novel immune checkpoint inhibitor with an intact Fc region. Tiragolumab selectively binds to TIGIT, a novel inhibitory immune checkpoint which suppresses the immune response to cancer. Based on preclinical research, tiragolumab is thought to work as an immune amplifier with other cancer immunotherapies such as Tecentriq® (atezolizumab). The TIGIT pathway is distinct but

1

🌟 Clinical Tips from the 20th Annual California Cancer Consortium Conference 2024 🌟 Reflecting on key takeaways from this year's conference, where experts shared groundbreaking insights in cancer research and treatment: 🔬 Expansion Cohorts in Early Phase Clinical Trials: Valuable or Not? 📝 How to Submit a Clinical Letter of Intent (LOI) to NCI/CTEP 🫁 Advances in Limited and Extensive Stage Small Cell Lung Cancer 💡 New Biomarkers in Breast Cancer ⚡ Novel Targets in Hematologic Malignancies These sessions highlighted cutting-edge advancements and strategies shaping the future of oncology. Excited to see where these innovations will lead! #CaliforniaCancerConsortium #CancerResearch #ClinicalTrials #SmallCellLungCancer #BreastCancer #HematologicMalignancies #Oncology #ClinicalTips #MedicalInnovation #NCI #CancerCare Primo Lara Timothy Synold Jonathan Riess Paul Frankel Percy Ivy Tycel Phillips

7

Eliah Shamir and Hannah Bender from Genentech and Si Wu from AbbVie will share how #pathology as a discipline is making an impact in #tissuebased research and the #discovery and #development of new drugs to address unmet medical needs! Check out the full #Pathobiology2025 program https://bit.ly/3yOeuxu

29

1 Comment

💡 Feature Article 💡 In our latest #BioTuesdays feature, Adi Zuloff-Shani, Ph.D., CEO of Clearmind Medicine (NASDAQ: CMND; FSE: CWY0), discusses how their novel molecule, MEAI, is disrupting binge behaviors by targeting key neural pathways to treat alcohol use disorder (AUD). With FDA-approved clinical trials underway and innovative products like an MEAI-based beverage, Clearmind is poised to revolutionize treatments for AUD and beyond. 🔗 https://lnkd.in/gi4SfYKb Kilmer Lucas Inc.

7

1 Comment

Ten Companies to Watch in AI Drug Discovery https://lnkd.in/gCWtSdiZ In AI-based drug discovery—a field benefiting from a cumulative investment of $60 billion—the leaders are making real progress toward approved therapies. The post Ten Companies to Watch in AI Drug Discovery appeared first on GEN [...] #LosAngeles #OrangeCountyCA #Biotech #Lifescience #News

1

Christian Ramirez Amarilla now at #BITS2024 about how inhibiting METTL3, an important RNA methyltransferase, affects RNA structure, adenosine-to-inosine (A-to-I) editing, and the immune response in leukemia models, providing new insights into potential therapeutic approaches for leukemia. #Bioinformatics #LeukemiaResearch #BITS2024

53

Latest on MDMA rejection; Novo vs. Lilly earnings; Recursion, Exscientia to merge; Q&A with Genentech CEO; and more https://lnkd.in/gRuf3XRp Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up [...] #LosAngeles #OrangeCountyCA #Biotech #Lifescience #News

1

#PRIMR produces doctor-approved videos for trustworthy trial content. The RadiCaL Study is enrolling kidney cancer patients with bone metastases to explore if adding Ra-223 to cabozantinib improves patient outcomes. PI: Rana McKay UC San Diego Alliance for Clinical Trials in Oncology See IRB-approved video below 👇 https://lnkd.in/d97fj9dj #kidneycancer #kidneycancerawareness #cabozantinib #radium223 #radiopharmaceuticals #clinicaltrials #cancer #clinicalresearch #DEI #digital #health #immunotherapy #kidneycancer #men #menshealth #metastatickidneycancer #oncology #patienteducation #video #women #womenshealth #digital

1